Autor: |
de Boni, Laura, Odainic, Alexandru, Gancarczyk, Natalie, Kaluza, Luisa, Strassburg, Christian P., Kersting, Xenia A. K., Johnson, Joseph M., Wüllner, Ullrich, Schmidt, Susanne V., Nattermann, Jacob, Petzold, Gabor C. |
Předmět: |
|
Zdroj: |
Neurological Research & Practice; 10/31/2022, Vol. 4 Issue 1, p1-7, 7p |
Abstrakt: |
Recent studies have indicated that long-term neurological sequelae after COVID-19 are not accompanied by an increase of canonical biomarkers of central nervous system injury in blood, but subgroup stratifications are lacking. This is a particular concern in chronic headache, which can be a leading symptom of Post-COVID diseases associated with neuronal damage such as vasculitis or autoimmune encephalitis. We here compared patients with mild Post-COVID-19 syndrome and persistent headache (persistent Post-COVID-19 headache) lasting longer than 12 weeks after the initial serological diagnosis, to patients with mild and severe COVID-19 and COVID-19-negative controls. Levels of neurofilament light chain and glial fibrillary astrocytic protein, i.e. markers of neuronal damage and reactive astrogliosis, were lower in blood from patients with persistent Post-COVID-19 headache compared to patients with severe COVID-19. Hence, our pilot serological study indicates that long-term Post-COVID-19 headache may not be a sign of underlying neuronal damage or neuroinflammation. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|